Delays to product launches have caused GN to revise its 2021 financial guidance for GN Hearing.
The product delays are due to a postponement of component deliveries, which were needed in product development.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Hearing firms urge FDA to increase OTC safety requirements
A number of the world’s biggest hearing aid manufacturers have come together to encourage the US health authority to tighten the safety requirements for OTC hearing aids, which will hit the shelves in the US sometime this year.
Novo Nordisk launches oral semaglutide in India
Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.
Coloplast initiates trial of ostomy leakage product
The medtech company will being clinically testing its ostomy add-on product, Heylo, in January.
Top news from MedWatch this week
Miss anything?
Danish bank cuts Genmab price target, retains "buy" recommendation
Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.
QA Specialist 
KLIFO is looking for a Director, Business Support for our Glostrup office 
GxP QA Compliance Manager for Quality Assurance 
Senior Key Account Manager 
Lead Scientist, Global STA, Royal DSM/Glycom 
Senior Quality Assurance Consultant, Denmark 
QA Specialist, GMP QA 
Compound Development Team Lead 
NORDIC Medical Sales Director 
Chemists are wanted for ALK's internal Aircraft Corps 
Director Regulatory Affairs 
Senior Director, Global Regulatory Lead 
Director Medical Science 
QA Manager GMP/GDP Compliance & Audits 
Health Economist